News | Heart Valve Technology | April 15, 2016

First Data Presented on Medtronic Harmony Transcatheter Pulmonary Valve

Encouraging Early Outcomes from Rigorously Designed Study Set the Stage for IDE 


Harmony trabnscatheter pulmonary valve

April 15, 2016 — The first clinical data on the Medtronic Harmony Transcatheter Pulmonary Valve (TPV) from its early feasibility study, demonstrated positive initial outcomes at six-months in patients with an indication for pulmonary valve restoration. The initial results were presented during the American College of Cardiology (ACC) 2016 meeting. Following the positive initial data, a pivotal investigational device exemption (IDE) study is planned to start in late calendar year 2016, pending approval from the U.S. Food and Drug Administration (FDA).
The first-of-its-kind early feasibility study was initiated by Medtronic in close collaboration with the FDA in an effort to develop a minimally invasive alternative to open-heart surgery for patients with congenital heart disease (CHD). Approximately one in five patients born with congenital heart disease have an abnormality of their right ventricular outflow tract (RVOT).  In these patients, there are primarily two options currently used to facilitate blood flow from the heart to the lungs: an open surgical valve replacement (80 percent) or an open surgical valve-conduit implant (20 percent). In the latter case, when the conduit fails, a non-surgical valve such as the globally approved Medtronic Melody Transcatheter Pulmonary Valve (TPV) System — which helps restore pulmonary valve function and delays additional surgical intervention — may be an option. The Harmony TPV may prove to be a less invasive option for approximately 80 percent of patients who currently undergo initial open heart surgical valve replacement to restore normal valve function,

“Through precise patient selection, the early feasibility data enables the clinical community to gather several key insights that  will help to determine the valve’s therapeutic benefits in this patient population,” said John Cheatham, M.D., director of cardiac catheterization and interventional therapy and co-director of The Heart Center at Nationwide Children's Hospital in Columbus, Ohio, as well as the presenter of the data at ACC. “Due to its unique design and ability to adapt to a wide variety of patient anatomies,  the Harmony TPV and its future iterations may provide a broad range of CHD patients with a minimally invasive treatment option that allows for shorter procedural time and hospital stay.”
The early feasibility study for the Harmony TPV is a non-randomized, prospective study at two sites in the United States and one in Canada. The study included a rigorous patient selection process to identify 20 patients for implant and follow-up out to five years. Due to the highly variable anatomy of the patient population, the study required careful screening to ensure the optimal fit.

Of the patients followed out to six months (N=18), severe pulmonary regurgitation improved from 95 percent pre-implant to 0 percent at six months. In addition, mean RVOT gradients were consistent and stable from 13.2 ± 5.1 mmHg at discharge and 15.4 ± 5.6 mmHg at six months. Some gradients are expected in this patient population due to the right side of the heart having free-blood flow before the valve is implanted. 
“We are very encouraged by the positive early outcomes with the Harmony TPV. We look forward to partnering closely with the FDA to further continue our research with leading physicians to address an unmet need for this specific patient population,” said Rhonda Robb, vice president and general manager of the Heart Valve Therapies business, part of the cardiac and vascular group at Medtronic. “This clinical milestone underscores our commitment to broadening our congenital heart disease program as we bring new treatment solutions to this underserved patient group.”
The Harmony TPV is not available in the United States and is available for investigational use only. The minimally invasive congenital heart disease technology builds off of the proven Melody TPV platform, the first transcatheter heart valve available anywhere in the world.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Overlay Init